Formalise knowledge on population-level exposure assessment. Public deliverable 3.3
Creators: name: Pimenoff, Ville
name: Lehtinen, Matti
Publisher: name: Zenodo
Year: 2023
Subjects: exposome
research
data cohort
hpv vaccination

description: This deliverable describes the continuously expanding, comprehensive exposure assessment over time in a population-based collection of cytological/nucleic acid samples from multiple anatomical sites and serum samples from two randomised screening cohorts of over 15.000 1992-97 born women. The women received or refused prophylactic human papillomavirus vaccination as early adolescents in 2007-2010 and have attended randomised cervical screening every third year since 2014. Based on informed consent, the serial samples are available for high-throughput laboratory analyses on the extent of sexually transmitted infection (STI) exposures and their sequelae in fertile-aged Finnish females as population standardised prevalence, incidence and cumulative incidence rate ratios for up to 15 years.The Finnish HPV Vaccine Cohort (F-VAC) is comprised of the two largest randomised human papillomavirus (HPV) intervention cohorts, which originated from overlapping sources. The first is a community randomised phase IV trial assessing the impact of girls-only or gender-neutral HPV vaccination strategies. The second and overlapping is a set of two individually randomised trials examining the frequency of cervical screening in HPV-vaccinated and unvaccinated women. In 2007, 80,272 early adolescents aged 12 to 15 were invited to participate in the phase IV trial across 33 Finnish towns. Of the 39,420 girls, 20,514 participated, and 12,402 received three doses of HPV16/18 vaccine between 2007 and 2010. From 2010 to 2014, 2,298 adolescent females received HPV16/18 vaccination at age 18 during the first follow-up visit. This group stemmed from originally hepatitis B-virus (HBV) vaccinated 3,572 early adolescents and 1,836 unvaccinated similarly-aged femalesSimultaneously, an overlapping 2014 individually randomised trial assessed the accuracy of infrequent vs. frequent screening of HPV-vaccinated women. Three additional follow-up visits with cervical and blood sampling occurred at ages 22 (6,959 participants), 25 (6,381 participants), and 28 (over 4,489 participants). In addition, 1,258 unvaccinated women who originally refused or were too young to participate in the community-randomized HPV vaccination trial or Finnish national HPV vaccination program have participated in a parallel randomised trial on frequent vs. infrequent screening of herd effect protected women.Participation in the phase IV trial required parental consent, while participation in the cervical screening trial and subsequent follow-up visits required informed consent. The F-VAC includes demographic information, residential and vaccination history, comprehensive sexually transmitted infection status (not HIV) at DNA and/or serology levels, cervical cytology and histology data, and smoking habits (at ages 25 and 28). The use of this population-wide HPV vaccination data follows the regulations outlined in the Finnish Biobank Act §§26 & 27 and is governed by the Findata instructions for data protection and security (www.findata.fi).